Alpelisib
About
Therapy type: Targeted therapy
Therapy strategy: PI3K/AKT/mTOR inhibition
Mappings
NCI Thesaurus: Alpelisib (ncit:C94214)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | ER positive, HER2-negative, PIK3CA somatic variants | Invasive Breast Carcinoma | Alpelisib, Fulvestrant | |
| FDA (1) | HER2-negative, PIK3CA somatic variants, PR positive | Invasive Breast Carcinoma | Alpelisib, Fulvestrant | |
| FDA (1) | ER positive, HER2-negative, PIK3CA somatic variants, PR positive | Invasive Breast Carcinoma | Alpelisib, Fulvestrant | |
| EMA (1) | ER positive, HER2-negative, PIK3CA somatic variants | Invasive Breast Carcinoma | Alpelisib, Fulvestrant | |
| EMA (1) | HER2-negative, PIK3CA somatic variants, PR positive | Invasive Breast Carcinoma | Alpelisib, Fulvestrant | |
| EMA (1) | ER positive, HER2-negative, PIK3CA somatic variants, PR positive | Invasive Breast Carcinoma | Alpelisib, Fulvestrant |